Navigation Links
Peregrine Pharmaceuticals Reports Studies Published in 'Science' Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
Date:5/13/2008

immune system recognition and destruction, a key secondary mechanism we believe is operative in both the anti-viral and anti-cancer applications of our anti-PS technology."

In a separate Science Perspective article discussing the studies(3), the commentators note that the essential role of PS may not be limited to vaccinia infections, but may also play a role in HIV infection. Vaccinia and HIV are both enveloped viruses, and as the articles discuss, PS becomes exposed on the surface of enveloped viruses and the cells they infect. This is consistent with findings by Peregrine researchers showing that its anti-PS antibodies bind to every enveloped virus tested. The company's anti-PS antibodies have also demonstrated promising anti-viral activity against a number of enveloped viruses in preclinical tests, as well as in clinical trials in patients infected with HCV, which is an enveloped virus. In addition to the ongoing clinical trial in HCV patients co-infected with HIV, Peregrine's anti-PS antibodies are currently being studied in animal models of HIV.

Peregrine's anti-PS technology is exclusively licensed from the University of Texas Southwestern Medical Center at Dallas, where Dr. Philip Thorpe has been a pioneer in investigating the role of anti-phosphatidylserine therapies in viral infections and cancer for more than a decade.

"It is gratifying to see the growing momentum of scientific interest and inquiry in the unique role of PS in immune system function and dysfunction," said Dr. Thorpe. "Our extensive work in the potential of anti-PS therapies for treating virus infections and cancer has been predicated on the same types of mechanisms that are elucidated and discussed in these first-rate studies, and we welcome the independent corroboration and additional insights that this new research is providing to the field."

About Peregrine's Anti-PS Antibody Bavituximab

Peregrine's clinical stage monoclonal antibody bavituximab is in
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
2. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
3. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
4. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
8. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
9. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
10. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
11. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 04, 2015 Proove Biosciences ... Medicine, is excited to announce the launch of ... Optimize the Management of Pain”. , The continuing ... for the next year. The focus of the ... recognize inadequate pain treatments, integrate appropriate pain management ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, ... and technology provider, today announced that clinical ... countries convened at its annual European User ... to discuss the use of its ... BioClinica,s eClinical technologies include: the Microsoft Office-Smart ...
(Date:3/4/2015)... Follow us on LinkedIn ... fastest growing technologies in the life sciences industry. Growing ... driving growth in nucleic acid detection technologies like qPCR ... expressions will continue to benefit the qPCR and dPCR ... from pharma, biotech, food & beverage to animal feed, ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... Increase needed to train workforce, stimulate economy ALEXANDRIA, Va., ... Fiscal Year 2010 budget request, proposing level funding for ... (Perkins Act) at $1.3 billion. The Perkins Act is ... education programs that connect education and real-world careers. The ...
... the world,s leading publishers of scientific, technical, and ... Michael Hansen,CEO of Elsevier,s Health Sciences Division, issued ... improper Australia based sponsored journal,publication practices between 2000 ... prides itself on operating its business in the ...
... May 7 The Sixth Annual Healthcare Unbound Conference ... (TCBI), will feature the coming together of consumer and ... The Conference will take place at the ... 2009. Attendees will include a diverse representation of ...
Cached Biology Technology:Obama Budget Level Funds Career Technical Education 2Obama Budget Level Funds Career Technical Education 3Statement From Michael Hansen, CEO of Elsevier's Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 3
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... , New research published today in BioMed Central,s open access ... plant Rafflesia cantleyi , with its 50cm diameter flowers, ... Analysis of these genes shows that their functions range from ... replaced the parasites own gene activity. Vertical gene transfer ...
... N.H. Communities of microbial organisms -- species such ... the Gulf of Mexico changed significantly following the Deepwater ... University of New Hampshire,s Hubbard Center for Genome Studies ... sediments from five Gulf Coast sites prior to and ...
... of Colorado Boulder looking for organisms that eke out a ... has found a hardy few. A new DNA analysis ... in South America has revealed a handful of bacteria, fungi ... a different way of converting energy than their cousins elsewhere ...
Cached Biology News:Parasitic plants 'steal' genes from their hosts 2Microbial communities shifted dramatically after Deepwater Horizon spill 2CU-Boulder-led team finds microbes in extreme environment on South American volcanoes 2CU-Boulder-led team finds microbes in extreme environment on South American volcanoes 3CU-Boulder-led team finds microbes in extreme environment on South American volcanoes 4